Emerging Markets Report: A Mushroom Monster in the Making
Hypha Labs’ Micro Pearls™ Could be to Mushrooms What Keurig is to Coffee
An Emerging Markets Sponsored Commentary
ORLANDO, Fla., Oct. 17, 2024 (GLOBE NEWSWIRE) — Today’s featured profile ticks all the boxes for us when we are looking at a potential investment . It is a potential monster in the exploding mushroom industry with proprietary game-changer technology and a compelling path to market.
We believe potential for enormous sales in a direct-to-consumer market and in commercial kitchens is highly compelling.
Let’s get right to the point. Hypha Labs (OTCQB: FUNI) has INVENTED both a home and commercial device to produce top notch functional mushroom ingredients in eight days or so using a compact device that easily sits on a countertop.
That means Mom or Dad can take the proprietary solution for the functional mushroom of choice, drop it in the company’s patent-pending Mushroom Accelerator and again, in just days a tidy crop of MicroPearls™ are ready to be added to a coffee or a meal. This avoids the pitfalls and unpleasantness of growing mushrooms in animal feces and creates predictable genetics each and every time.
Reishi, Lion’s Mane, Cordyceps, Turkey Tail, Agarikon, and Chaga and more types of mushrooms …all from the privacy of home, each an integral component of the massive $31 billion functional mushroom market. And yes, many more mushroom varieties not listed here can be produced using Hypha’s groundbreaking device.
They are just getting started, and it appears, so is America with mushroom use of all varieties on a steep incline.
We think that Hypha Labs could be to mushrooms what the Keurig was to coffee, an efficient, predictable way for consumers to create their own ingredients. And good coffee was already widely available to be produced at home. This is not the case with mushrooms.
Take a look at this nifty one minute video of the process and ask yourself if this could be the market disruptive game-changer we anticipate:
https://www.hyphalabs.com/#watch
We intend to review Hypha Labs for the next couple months and to closely track their development and execution of their business model.
If you see what we see, we suggest you add the ticker “FUNI’ to your watchlist and take a moment to review the Company’s Investor Presentation at the following link:
www.hyphalabs.com/deck
About Hyphalabs Inc.
The company has developed revolutionary, cutting-edge technology focused on new methods of producing the active ingredients found in a wide array of functional mushrooms using its patent-pending mushroom accelerators. The Company is positioning itself to play an important role in the burgeoning Functional Mushroom industry in addition to being a disruptive force in future and emerging mushroom opportunities. Visit us at HyphaLabs.com.
About The Emerging Markets Report:
The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stockbrokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.
For more informative reports such as this, please sign up at https://emergingmarketsconsulting.com/alerts/
Must Read OTC Markets/SEC policy on stock promotion and investor protection
- https://www.otcmarkets.com/learn/policy-on-stock-promotion
- https://www.otcmarkets.com/learn/investor-protection
- https://www.sec.gov/news/press-release/2017-79
- https://www.sec.gov/oiea/investor-alerts-bulletins/ia_promotions.html
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.
EMC has been paid $50,000 on behalf of Hyphalabs Inc. and will receive an additional $50,000 in 15 days for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. | Please read our full disclaimer.
For media inquiries, please contact Maggie Caraway at maggie@emergingmarketsconsulting.com
Emerging Markets Consulting, LLC
Florida Office
15701 State Road 50, Suite #205
Clermont, FL 34711
E-mail: jamespainter@emergingmarketsllc.com
Web: https://emergingmarketsconsulting.com/
